419 related articles for article (PubMed ID: 18803648)
1. CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer's disease.
Haense C; Buerger K; Kalbe E; Drzezga A; Teipel SJ; Markiewicz P; Herholz K; Heiss WD; Hampel H
Eur J Neurol; 2008 Nov; 15(11):1155-62. PubMed ID: 18803648
[TBL] [Abstract][Full Text] [Related]
2. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.
Chiaravalloti A; Barbagallo G; Ricci M; Martorana A; Ursini F; Sannino P; Karalis G; Schillaci O
Brain Res; 2018 Jan; 1678():116-122. PubMed ID: 29066367
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.
Petrie EC; Cross DJ; Galasko D; Schellenberg GD; Raskind MA; Peskind ER; Minoshima S
Arch Neurol; 2009 May; 66(5):632-7. PubMed ID: 19433663
[TBL] [Abstract][Full Text] [Related]
4. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
[TBL] [Abstract][Full Text] [Related]
5. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial.
Wang T; Huang Q; Reiman EM; Chen K; Li X; Li G; Lin Z; Li C; Xiao S
J Clin Psychopharmacol; 2013 Oct; 33(5):636-42. PubMed ID: 23948786
[TBL] [Abstract][Full Text] [Related]
6. Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment.
Fellgiebel A; Siessmeier T; Scheurich A; Winterer G; Bartenstein P; Schmidt LG; Müller MJ
Biol Psychiatry; 2004 Aug; 56(4):279-83. PubMed ID: 15312816
[TBL] [Abstract][Full Text] [Related]
7. How the cognitive reserve interacts with β-amyloid deposition in mitigating FDG metabolism: An observational study.
Carapelle E; Serra L; Modoni S; Falcone M; Caltagirone C; Bozzali M; Specchio LM; Avolio C
Medicine (Baltimore); 2017 Apr; 96(16):e5876. PubMed ID: 28422821
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer's disease.
Liguori C; Chiaravalloti A; Sancesario G; Stefani A; Sancesario GM; Mercuri NB; Schillaci O; Pierantozzi M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2040-9. PubMed ID: 27221635
[TBL] [Abstract][Full Text] [Related]
9. Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer's disease.
Yakushev I; Muller MJ; Buchholz HG; Lang U; Rossmann H; Hampel H; Schreckenberger M; Fellgiebel A
Curr Alzheimer Res; 2012 Feb; 9(2):241-7. PubMed ID: 22044023
[TBL] [Abstract][Full Text] [Related]
10. The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.
Dowling NM; Johnson SC; Gleason CE; Jagust WJ;
Neuroimage; 2015 Jan; 105():357-68. PubMed ID: 25450107
[TBL] [Abstract][Full Text] [Related]
11. In Vivo Assessment of Tau Deposition in Alzheimer Disease and Assessing Its Relationship to Regional Brain Glucose Metabolism and Cognition.
Baghel V; Tripathi M; Parida G; Gupta R; Yadav S; Kumar P; Dey AB; Damle NA; Kumar R; Bal C
Clin Nucl Med; 2019 Nov; 44(11):e597-e601. PubMed ID: 31584490
[TBL] [Abstract][Full Text] [Related]
12. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints.
Mosconi L; De Santi S; Brys M; Tsui WH; Pirraglia E; Glodzik-Sobanska L; Rich KE; Switalski R; Mehta PD; Pratico D; Zinkowski R; Blennow K; de Leon MJ
Biol Psychiatry; 2008 Mar; 63(6):609-18. PubMed ID: 17720148
[TBL] [Abstract][Full Text] [Related]
13. Neuronal injury biomarkers for assessment of the individual cognitive reserve in clinically suspected Alzheimer's disease.
Beyer L; Schnabel J; Kazmierczak P; Ewers M; Schönecker S; Prix C; Meyer-Wilmes J; Unterrainer M; Catak C; Pogarell O; Perneczky R; Albert NL; Bartenstein P; Danek A; Buerger K; Levin J; Rominger A; Brendel M
Neuroimage Clin; 2019; 24():101949. PubMed ID: 31398553
[TBL] [Abstract][Full Text] [Related]
14. Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer's disease.
Arlt S; Brassen S; Jahn H; Wilke F; Eichenlaub M; Apostolova I; Wenzel F; Thiele F; Young S; Buchert R
Eur J Nucl Med Mol Imaging; 2009 Jul; 36(7):1090-100. PubMed ID: 19219430
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease.
Leuzy A; Cicognola C; Chiotis K; Saint-Aubert L; Lemoine L; Andreasen N; Zetterberg H; Ye K; Blennow K; Höglund K; Nordberg A
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1152-1163. PubMed ID: 30610252
[TBL] [Abstract][Full Text] [Related]
16. Functional correlates of t-Tau, p-Tau and Aβ₁₋₄₂ amyloid cerebrospinal fluid levels in Alzheimer's disease: a ¹⁸F-FDG PET/CT study.
Chiaravalloti A; Martorana A; Koch G; Toniolo S; di Biagio D; di Pietro B; Schillaci O
Nucl Med Commun; 2015 May; 36(5):461-8. PubMed ID: 25646706
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic.
Morinaga A; Ono K; Ikeda T; Ikeda Y; Shima K; Noguchi-Shinohara M; Samuraki M; Yanase D; Yoshita M; Iwasa K; Mastunari I; Yamada M
Dement Geriatr Cogn Disord; 2010; 30(4):285-92. PubMed ID: 20861634
[TBL] [Abstract][Full Text] [Related]
18. Brain metabolic correlates of cerebrospinal fluid beta-amyloid 42 and tau in Alzheimer's disease.
Vukovich R; Perneczky R; Drzezga A; Förstl H; Kurz A; Riemenschneider M
Dement Geriatr Cogn Disord; 2009; 27(5):474-80. PubMed ID: 19439965
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid tau protein levels and 18F-fluorodeoxyglucose positron emission tomography in the differential diagnosis of Alzheimer's disease.
Yakushev I; Bartenstein P; Siessmeier T; Hiemke C; Scheurich A; Lotz J; Fellgiebel A; Müller MJ
Dement Geriatr Cogn Disord; 2010; 30(3):245-53. PubMed ID: 20847555
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
Alexander GE; Chen K; Pietrini P; Rapoport SI; Reiman EM
Am J Psychiatry; 2002 May; 159(5):738-45. PubMed ID: 11986126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
